Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
Acq. announced
Appointed director
INSITE VISION INC (INSV) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/02/2015 8-K Quarterly results
09/28/2015 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Amended and Restated Agreement and Plan of Merger, by and among the Company, Ranbaxy and Merger Sub, as amended and restated September 28, 2015"
09/15/2015 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Ob...
Docs: "Agreement and Plan of Merger, by and among the Company, Ranbaxy and Merger Sub",
"Secured Note, by and between the Company and Ranbaxy",
"Security Agreement, by and between the Company and Ranbaxy",
"IP Security Agreement, by and between the Company and Ranbaxy",
"Form of Amendment, Waiver and Consent Agreement",
"InSite Vision and Sun Pharma Enter into Merger Agreement Shareholders Will Receive $0.35 per Share in Cash at Closing InSite Terminates Merger Agreement with QLT Inc."
09/04/2015 8-K Other Events, Financial Statements and Exhibits
Docs: "InSite Vision Determines that an Unsolicited Offer from a Global Pharmaceutical Company to Acquire InSite for $0.35 per Share in Cash Constitutes a “Company Superior Proposal” Bidder Favorably Concludes Due Diligence on Recent BromSite ™ Patent Lawsuit"
09/03/2015 8-K Other Events, Financial Statements and Exhibits
Docs: "InSite Vision Receives Second Unsolicited Acquisition Proposal for $0.35 per Share from a Global Pharmaceutical Company ALAMEDA, Calif. - September 3, 2015 — InSite Vision Inc. today announced that the Company has received a second unsolicited proposal from a global pharmaceutical company to acquire all outstanding shares of InSite Vision common stock at an increased price of $0.35 per share in cash. The proposal is only subject to due diligence regarding the recently filed BromSite™ patent lawsuit. InSite Vision believes the lawsuit is without merit. InSite Vision is party to a merger agreement with QLT Inc. pursuant to which QLT would acquire InSite Vision in a transaction in which InSite Vision's stockholders would receive 0.078 QLT shares for each share of InSite Vision stock, subject ..."
09/03/2015 8-K Other Events
08/27/2015 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Second Amended and Restated Agreement and Plan of Merger, by and among the Company, QLT and Merger Sub",
"InSite Vision and QLT Amend Merger Agreement InSite Board Determines Previously Announced Unsolicited Binding Offer from a Multi-National Pharmaceutical Company No Longer Constitutes a “Company Superior Proposal”"
08/21/2015 8-K Other Events, Financial Statements and Exhibits
Docs: "InSite Vision Determines that an Unsolicited Offer from a Multi-National Pharmaceutical Company to Acquire InSite for $0.25 in Cash Constitutes a “Company Superior Proposal”"
08/11/2015 8-K Other Events
08/11/2015 8-K Quarterly results
Docs: "InSite Reports Second Quarter 2015 Financial Results"
08/10/2015 8-K Other Events, Financial Statements and Exhibits
Docs: "InSite Vision Receives Unsolicited Proposal from a Multi-National Pharmaceutical Company ALAMEDA, Calif. - August 10, 2015 — InSite Vision Inc. today announced that InSite Vision has received an unsolicited proposal from a multi-national pharmaceutical company pharmaceutical company to acquire all outstanding shares of InSite Vision common stock at a price of $0.25 per share in cash. The proposal is non-binding and is subject to further due diligence. As previously announced, InSite Vision is party to a merger agreement with QLT Inc. pursuant to which QLT would acquire InSite in an all-stock transaction in which InSite Vision's stockholders would receive 0.048 QLT shares for each share of InSite Vision that they hold. Consistent with its fiduciary duties and in accordance with its existing..."
06/11/2015 8-K Acquisition/merger/asset purchase announced
Docs: "Intercreditor Agreement, among the Company, QLT and U.S. Bank, as collateral agent",
"Form of Amendment, Waiver and Consent",
"InSite Vision Announces Completion of the New Drug Application Submission to"
06/09/2015 8-K Other Events, Financial Statements and Exhibits
Docs: "Investor Presentation Slides",
"Conference Call Transcript"
06/08/2015 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Agreement and Plan of Merger, by and among the Company, QLT and Merger Sub",
"Secured Note, by and between the Company and QLT",
"Security Agreement, by and between the Company and QLT",
"IP Security Agreement, by and between InSite Vision Incorporated and QLT Inc",
"InSite Vision to Merge with Canadian Biotechnology Company QLT"
05/12/2015 8-K Quarterly results
Docs: "InSite Vision Reports First Quarter 2015 Financial Results"
04/17/2015 8-K Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregister...
04/02/2015 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
Docs: "Certificate of Amendment to the Restated Certificate of Incorporation of InSite Vision Incorporated"
02/17/2015 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "InSite Vision Reports Fourth Quarter and Year-End 2014 Financial Results"
02/04/2015 8-K Entry into a Material Definitive Agreement
12/19/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "InSite Vision Announces Date for Annual Stockholder Meeting"
11/05/2014 8-K Quarterly results
Docs: "InSite Vision Reports Third Quarter 2014 Financial Results"
10/16/2014 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Form of Warrant",
"Securities Purchase Agreement",
"Security Agreement",
"Form of Note"
08/13/2014 8-K Quarterly results
Docs: "InSite Vision Reports Second Quarter 2014 Financial Results"
07/31/2014 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Form of Indemnification Agreement between the Company and its directors and officers and other designated employees"
07/22/2014 8-K Submission of Matters to a Vote of Security Holders
06/13/2014 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Note Purchase Agreement, entered into on June 10, 2014, between Azithromycin Royalty Sub LLC and the noteholders party thereto",
"Third Amendment to License Agreement, entered into on June 10, 2014, between InSite Vision Incorporated, Akorn, Inc. and Inspire Pharmaceuticals"
05/14/2014 8-K Quarterly results
Docs: "InSite Vision Reports First Quarter 2014 Financial Results"
05/08/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "INSITE VISION INCORPORATED PRESS RELEASE DATED MAY 8, 2014"
03/27/2014 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "InSite Vision Reports Fourth Quarter and Full-Year 2013 Financial Results"
11/12/2013 8-K Form 8-K - Current report
08/08/2013 8-K Quarterly results
Docs: "InSite Vision Reports Second Quarter 2013 Financial Results Alameda, Calif., August 8, 2013 - InSite Vision Incorporated today reported financial results for the quarter ended June 30, 2013. Revenues for the second quarter of 2013 were $19.2 million compared to $1.8 million for the same period in 2012. Included in the second quarter of 2013 were revenues of $15 million for the sale of the Besivance royalty rights. Net income for the second quarter of 2013 was $12.1 million, or $0.09 per share, compared to a net loss of $6.8 million, or $0.05 per share, in the second quarter of 2012. “2013 continues to be a year of dedicated focus for InSite as we work with our clinical investigators and the FDA to advance our pipeline of ophthalmic therapeutics,” said Timothy Ruane, InSite's Chief Executiv..."
08/02/2013 8-K Entry into a Material Definitive Agreement
06/26/2013 8-K Entry into a Material Definitive Agreement
05/07/2013 8-K Quarterly results
Docs: "InSite Vision Reports First Quarter 2013 Financial Results"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy